Peptides as tools and drugs for immunotherapies

Beck, Alain; Klinguer‐Hamour, Christine; Bussat, Marie-Claire; Champion, Thierry; Haeuw, Jean‐François; Goetsch, Liliane; Wurch, Thierry; Sugawara, Masaaki; Milon, Alain; Dorsselaer, Alain Van; Nguyen, Thien Ngoc; Corvaı̈a, Nathalie

doi:10.1002/psc.852

Cited by 33 publications

(31 citation statements)

References 66 publications

(89 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Given these findings, the development of subunit vaccines against RSV appears more promising. Several RSV subunit vaccine formulations have been examined, including purified F protein (PFP) vaccines (4,5,18,23,35,44), and those targeting G protein. For example, BBG2Na is a G-protein subunit vaccine candidate that was shown to elicit robust immune responses in small and large animals (8,14,55), and has been evaluated in human clinical trials.…”

Section: Introductionmentioning

confidence: 99%

Antibodies to the Central Conserved Region of Respiratory Syncytial Virus (RSV) G Protein Block RSV G Protein CX3C-CX3CR1 Binding and Cross-Neutralize RSV A and B Strains

Choi¹,

Mason²,

Jones³

et al. 2012

Viral Immunology

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) is a primary cause of severe lower respiratory tract disease in infants, young children, and the elderly worldwide, and despite decades of effort, there remains no safe and effective vaccine. RSV modifies the host immune response during infection by CX3C chemokine mimicry adversely affecting pulmonary leukocyte chemotaxis and CX3CR1+ RSV-specific T-cell responses. In this study we investigated whether immunization of mice with RSV G protein polypeptides from strain A2 could induce antibodies that block G protein-CX3CR1 interactions of both RSV A and B strains. The results show that mice immunized with RSV A2 G polypeptides generate antibodies that block binding of RSV A2 and B1 native G proteins to CX3CR1, and that these antibodies effectively cross-neutralize both A and B strains of RSV. These findings suggest that vaccines that induce RSV G protein-CX3CR1 blocking antibodies may provide a disease intervention strategy in the efforts to develop safe and efficacious RSV vaccines.

show abstract

Section: Introductionmentioning

confidence: 99%

Antibodies to the Central Conserved Region of Respiratory Syncytial Virus (RSV) G Protein Block RSV G Protein CX3C-CX3CR1 Binding and Cross-Neutralize RSV A and B Strains

Choi¹,

Mason²,

Jones³

et al. 2012

Viral Immunology

View full text Add to dashboard Cite

show abstract

“…The clinical trial of respiratory syncytial virus (RSV) vaccine used an epitope selected strictly to contain the epitopes of both B cells and T cells. In the clinical trials, the effect of vaccination on RSV did not reach statistical significance [68,69].…”

Section: B Cell-based Peptide Vaccinementioning

confidence: 96%

B Cell Epitope-Based Vaccination Therapy

et al. 2015

View full text Add to dashboard Cite

Currently, many peptide vaccines are undergoing clinical studies. Most of these vaccines were developed to activate cytotoxic T cells; however, the response is not robust. Unlike vaccines, anti-cancer antibodies based on passive immunity have been approved as a standard treatment. Since passive immunity is more effective in tumor treatment, the evidence suggests that limited B cell epitope-based peptide vaccines may have similar activity. Nevertheless, such peptide vaccines have not been intensively developed primarily because humoral immunity is thought to be preferable to cancer progression. B cells secrete cytokines, which suppress immune functions. This review discusses the possibility of therapeutic antibody induction by a peptide vaccine and the role of active and passive B cell immunity in cancer patients. We also discuss the use of humanized mice as a pre-clinical model. The necessity of a better understanding of the activity of B cells in cancer is also discussed.

show abstract

“…In addition, gemtuzumab ozogamicin has been approved in Japan. 50 At present, more than 40 ADCs are at the stage of clinical trials, and by the year 2018, the ADC market is expected to reach $28 billion.…”

Section: Lc/ms/ms Analysis Of the Adcsmentioning

confidence: 99%

Current Mass Spectrometric Tools for the Bioanalyses of Therapeutic Monoclonal Antibodies and Antibody-Drug Conjugates

et al. 2018

View full text Add to dashboard Cite

The increase in the use of therapeutic monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs) has made the detailed bioanalysis of these drugs essential not only for planning optimal therapeutic programs for clinical practice, but also for evaluating the biological equivalencies in the development of other biosimilars. The ligand binding assays that are widely in use now are being replaced rapidly by the highly accurate, sensitive, and selective analytical method using a mass spectrometer. This review will discuss the progress in and challenges observed during the development of a mass spectrometry-based bioanalytical method for therapeutic mAbs and ADCs.

show abstract

Peptides as tools and drugs for immunotherapies

Cited by 33 publications

References 66 publications

Antibodies to the Central Conserved Region of Respiratory Syncytial Virus (RSV) G Protein Block RSV G Protein CX3C-CX3CR1 Binding and Cross-Neutralize RSV A and B Strains

Antibodies to the Central Conserved Region of Respiratory Syncytial Virus (RSV) G Protein Block RSV G Protein CX3C-CX3CR1 Binding and Cross-Neutralize RSV A and B Strains

B Cell Epitope-Based Vaccination Therapy

Current Mass Spectrometric Tools for the Bioanalyses of Therapeutic Monoclonal Antibodies and Antibody-Drug Conjugates

Contact Info

Product

Resources

About